 Termination slow antirheumatic therapy rheumatoid arthritis prospective evaluation consecutive starts continuous observation period clinical data patients rheumatoid arthritis RA outpatient clinic seventy-one patients new administrations slow antirheumatic drugs patient years observation median time discontinuation intramuscular gold auranofin hydroxychloroquine penicillamine years years methotrexate vs drugs Adverse reactions common reason discontinuation efficacy common patients methotrexate disease duration disease severity demographic factors useful predictors discontinuation controlled clinical trials long-term outcome assessments measurement time termination practical tool drug inefficacy